LEADER 03320nam  22005653u 450 
001 996339118003316
005 20230829003032.0
010   $a1-280-75120-7
010   $a9786610751204
010   $a1-84692-549-5
035   $a(CKB)1000000000554616
035   $a(EBL)362710
035   $a(OCoLC)437229079
035   $a(SSID)ssj0000311400
035   $a(PQKBManifestationID)12134079
035   $a(PQKBTitleCode)TC0000311400
035   $a(PQKBWorkID)10332561
035   $a(PQKB)11323294
035   $a(Au-PeEL)EBL362710
035   $a(CaONFJC)MIL75120
035   $a(MiAaPQ)54803
035   $a(EXLCZ)991000000000554616
100   $a20130418d2006||||  u||            |
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aTherapeutic Strategies in Hypertension$b[electronic resource]
210   $aOxford $cAtlas Medical Publishing Ltd$d2006
215   $a1 online resource (185 p.)
225 1 $aTherapeutic Strategies
300   $aDescription based upon print version of record.
311   $a1-904392-41-5 
327   $aContents; Contributors; 1. Is there an ideal strategy for achieving blood pressure goals?; 2. Should metabolic syndrome patients with 'stage 2' pre-hypertension receive antihypertensive therapy?; 3. The presence of proteinuria and antihypertensive therapy selection; 4. Cholesterol, blood pressure and statins; 5. Do antihypertensive agents influence lipidprofiles and lipid therapy?; 6. How strong is the evidence for a blood pressure goal of less than 130/80mmHg for the high-risk patient?; 7. Approaches to cardiovascular risk reduction in patients with cardio-metabolic-renal risk
327   $a8. Should there be any reluctance to initiate combination antihypertensive therapy for patients with blood pressure of 160/100mmHg or higher?9. Is pulse pressure a predictor of therapeutic outcome?; 10. Should selection of antihypertensive therapy be focused on other markers for cardiovascular risk besides blood pressure?; 11. Can aggressive control of blood pressure prevent progression of kidney disease?; 12. Are there consequences for attempting to achieve blood pressure goals in the first week after a stroke?; 13. Diagnostic and therapeutic strategies in renal artery stenosis
327   $aAbbreviationsIndex
330   $aHypertension continues to be one of the leading causes of morbidity and mortality, significantly increasing the risk of stroke, myocardial infarction, heart failure and renal failure. It is one of the key risk factors in the metabolic syndrome, increasingly common in Western society. With such a complex aetiology, information on current antihypertensive therapy is extremely varied and dense. This new book presents a series of in-depth reviews by leading experts, bringing together in one volume the most up-to-date view on how antihypertensive therapies should be administered in a wide range of
410  0$aTherapeutic Strategies
606   $aHypertension
615  4$aHypertension.
676   $a616.13206
700   $aBakris$b George L.$f1952-$0898693
801  0$bAU-PeEL
801  1$bAU-PeEL
801  2$bAU-PeEL
906   $aBOOK
912   $a996339118003316
996   $aTherapeutic Strategies in Hypertension$92400551
997   $aUNISA